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Abstract 
The cdk inhibitor p21Cip1, also named p21Cip1/Waf1, is intimately involved in coupling 
growth arrest to cellular differentiation in several cell types. p21Cip1 is a multifunctional 
protein that might regulate cell-cycle progression at different levels. In a recent study 
we found no differences in the rate of proliferation between glial cells from wild-type 
and p21Cip1-/- mice. In the present study we examined differences in glial activation 
between glial cells from wild-type and p21Cip1-/- mice, using mixed glial cultures, 
microglia-enriched cultures and astrocyte-enriched cultures. We compared the effect of 
lipopolysaccharide and two forms (oligomeric and fibrillar) of the 1-42 -amyloid 
peptide on glial activation. We observed an attenuation of nuclear translocation of the 
nuclear factor kappa-B in p21Cip1-/- glial cells, when compared with glial cells from 
wild-type mice. In contrast, tumour necrosis factor- release was enhanced in p21Cip1-/-
microglial cells. In addition glial activation induced by lipopolysaccharide and the 
fibrillar form of the 1-42 -amyloid peptide upregulated p21Cip1. Our results support a 
role for p21Cip1 in the activation of glial cells, particularly in microglia.  
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Introduction
Glial cells play a key role in the normal function of the CNS. Under physiological 
conditions, brain glial cells are involved in the production of trophic factors, the 
maintenance of ionic homeostasis, buffering the action of neurotransmitters, immune 
surveillance and neural regeneration in the CNS (Kreutzberg, 1996; Anderson and 
Swanson, 2000, Farina et al., 2007). Microglia are the primary immune cells responsible 
for detecting invading pathogens and neuronal injury (Aloisi, 1999; Streit et al., 1999; 
Su and de Vellis, 2005; Hanisch and Kettenmann, 2007). Astroglial and microglial cells 
respond to neuronal damage, lesions, alterations in neuronal function, toxic agents and 
infectious agents. Their response involves morphological and functional changes, and is 
known as glial activation. Reactive astroglial and microglial cells upregulate the 
expression of a variety of factors, including growth factors, cytokines, chemokines, 
adhesion molecules, receptors, nitric oxide (NO), etc. These factors have neurotoxic or 
neuroprotective properties (Chao et al., 1995, Streit et al., 1999, Vitkovic et al., 2000, 
Herdegen and Waetzig, 2001, Hauwell et al., 2005, Butovsky et al., 2005, Block et al., 
2007, Kaushal and Schlichter, 2008). Several transcription factors participate in glial 
activation, including nuclear factor kappa-B (NF-B) (O’Neill and Kaltschmit, 1997; 
Tak and Firestein, 2001), peroxisome proliferator-activated receptors (PPARs) (Kielian 
and Drew, 2003), activated protein-1 (AP-1) (Herdegen and Waetzig, 2001) and some 
members of the CCAAT/enhancer binding proteins (C/EBPs) family of transcription 
factors (Pérez-Capote et al., 2006; Ejarque-Ortíz et al., 2007a and b). The cascade of 
microglial activation is a fine-tuned process that is also regulated by factors derived 
from neurons and other glial populations, in particular astrocytes. Astrocytes are local 
sources of transforming growth factor- (TGF-) and other immunomodulatory or 
neurotrophic factors, and the prominent role of astrocytes in inducing an 
immunologically silent state in microglial cells has been demonstrated in a number of 
experiments in vitro. Astrocytes can induce the transformation of ameboid into ramified 
microglial cells, and reduce proliferative activity (Wilms et al., 1997; Jones et al., 1998; 
Schilling et al., 2001; Kalla et al., 2003).
In a previous study (Tusell et al., 2005), we examined the role of the cell cycle inhibitor 
p21Cip in glial activation, using mixed glial cultures (approximately 75% astrocytes and 
25% microglia). This protein, also called WAF1, CAP20 or Sd1, is the founding 
member of the Cip/Kip family of CdKIs, which also includes p27 (Toyoshima and 
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Hunter, 1994) and p57 (Lee et al., 1995). p21Cip1 plays an essential role in growth arrest 
after DNA damage (Brugarolas et al., 1995), and its overexpression leads to G1 and G2 
(Niculescu et al., 1998) or S-phase arrest (Ogryzko et al., 1997). In addition, a variety of 
transcription factors (including STATs, C/EBP and C/EBP) that are induced by 
different stimuli activate p21Cip1 transcription. 
Here we examined whether p21Cip1is involved in the modulation of glial activation 
produced by LPS and fibrillar or oligomeric 1-42 -amyloid (A) peptide. We analysed 
the release of tumour necrosis factor- (TNF-), and the nuclear translocation of NF-
B. We also studied the expression of p21Cip1 after inducing glial activation. In 
summary, we show for the first time that LPS and fibrillar A upregulates p21Cip1 in 
cultured glial cells and taking into account all the results presented here, we conclude 
that p21Cip1 participates in the neurotoxic or neuroprotective effects associated with glial 
activation.
Material and Methods
Materials
Trypsin-EDTA solution (#25200-072), Dulbecco’s modified Eagle medium-F-12 
nutrient mixture (#31330-038), foetal bovine serum (#10270-106), penicillin-
streptomycin (#15140-114) and Fungizone (#15290-018) were from Invitrogen Ltd.
(Carlsbad, CA, USA). Deoxyribonuclease I (#D-5025), extravidin peroxidase (#E-
2886), laminin (#L-2020), cytosine arabinoside (#C-1768), hexafluoroisopropanol (#H-
8505), dimethyl sulfoxide (#D-4540), cycloheximide (#4859) and E. coli LPS serotype 
055:B5 (#L-6529) were from Sigma (St.Louis, MO, USA).  Alexa Fluor 488 goat anti-
mouse (#A11017) and Alexa Fluor 546 (#11010) goat anti-rabbit antibodies were from 
Molecular Probes (Eugene, OR, USA). PVDF membranes (#IPVH00010) were from 
Millipore (Bedford, MA, USA). HRP-labelled anti-rabbit antibody (#NA934) and ECL-
Plus (#RPN2132) were from Amersham (Buckinghamshire, UK). Protease inhibitor 
cocktail Complete (#1836145) was from Roche Diagnostics (Mannheim, Germany). 
Sensiscript RT enzyme was from Quiagen (Frankfurt, Germany).  Absolutely RNA 
Miniprep kit (#400800) was from Stratagene (La Jolla, CA, USA). Rabbit anti-NF-B 
p65 antibody (#sc-372) was from Santa Cruz Biotechnology (Temecula, CA, USA). 
Mouse anti-p21Cip1antibody (#OP76) was from Calbiochem (Darmstadt, Germany). 
Rabbit anti-TLR4 (#ab13556) was from Abcam (Cambridge, UK). Rabbit anti-GFAP 
Page 4 of 36
John Wiley & Sons, Inc.
GLIA
antibody (#Z 0334) was from DakoCytomation (Glostrup, Denmark). Biotinylated anti-
rabbit antibody (#31820) was from Pierce (Rockford, IL, USA). Rat anti-CD11b 
(#MCA711G, clone 5C6) was from Serotec (Oxford, UK). A1-42 peptide (#H-1368) 
was from Bachem AG (Bubendorf, Switzerland). VersaDoc system and Quantity One 
5.4.1 software were from Bio-Rad Laboratories (Hercules, CA, USA). Rabbit anti-p36 
antibody was a gift from Dr.Oriol Bachs (Faculty of Medicine, University of Barcelona, 
Spain).
Cell cultures and treatments
Experiments were carried out in accordance with the Guidelines of the European Union 
Council (86/609/EU), and the Spanish regulations (BOE 67/8509-12, 1988) for the use 
of laboratory animals. The study was approved by the Ethics and Scientific Committees 
of the Hospital Clínic de Barcelona. Mixed glial cultures were prepared from 1- or 2-
day-old neonatal p21Cip1+/+ or p21Cip1-/- mice both from the same C57BL/6 genetic 
background (Brugarolas et al., 1995). These mice were generously provided by Prof. 
Oriol Bachs (University of Barcelona, Spain) and were kept at the Animal facilities of 
the University of Barcelona. To obtain mixed glial cultures, mice cerebral cortices were 
dissected, carefully stripped of their meninges and digested with 0.25% trypsin for 25 
min at 37°C. Trypsinization was stopped by adding an equal volume of culture medium 
(Dulbecco’s modified Eagle medium-F-12 nutrient mixture, fetal bovine serum 10%, 
penicillin 100 U/mL, streptomycin 100 µg/mL and amphotericin B (Fungizone), 0.5 
µg/mL) to which 0.02% deoxyribonuclease I was added. The solution was pelleted (5 
min, 200 x g), resuspended in culture medium and brought to a single cell suspension by 
repeated pipetting followed by passage through a 105 µm pore mesh. Cells were seeded 
at a density of 250,000 cells/ml (=62,500 cells/cm2) and cultured at 37°C in humidified 
5% CO2-95% air. The medium was replaced every 5-7 days. Mouse mixed glial cultures 
reached confluence after 7-10 days in vitro and were used between 19 and 21 days in
vitro. At this point, they typically consisted of 75% type-I astrocytes and 25% 
microglia.
Mouse microglial cultures were prepared by mild trypsinization as described (Saura et 
al. 2003). Briefly, after 19-21 days in vitro mixed glial cultures were treated for 30 min 
with 0.06% trypsin in the presence of 0.25 mM EDTA and 0.5 mM Ca2+. This resulted 
in the detachment of an intact layer of cells containing virtually all the astrocytes, 
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leaving a population of firmly attached cells identified as >98% microglia. The 
microglial cultures were used twenty-four hours after isolation by this procedure.
Mouse astroglial cultures were prepared by seeding cortical cells prepared as for mixed 
glial cultures on laminin (20 µg/mL)-coated plates. Laminin-coating favours astroglial 
growth and inhibits microglial growth (Milner and Campbell 2002). When confluent, 
cultures were treated with 10 µM cytosine arabinoside for 4 days. Cultures were used 
one day after the end of cytosine arabinoside treatment. The vast majority of cells were 
type-I astrocytes. Less than 2% were microglia.
For immunocytochemistry studies cells were seeded in 48 well plates using a volume of 
300 µL/well. For the isolation of nuclear proteins from glial cultures, three, five or six 
950-mm2 wells of mixed glial, astroglial or microglial cultures, respectively, were used 
per condition using a total volume of 2000 µL/well.
Cell treatments: control cells were treated with culture medium. LPS was treated at 
0.1µg/mL. The oligomeric and fibrillar A forms were used at a final concentration of 5 
µM. 
Isolation of nuclear proteins
Cells were scrapped in cold PBS, and centrifuged for 4 min at 7000 x g, and the 
resulting pellet was resuspended in 400 µL of buffer A: 10 mM HEPES pH 7.9, 10 mM 
KCl, 0.1 mM EDTA, 1 mM phenylmethylsulphonyl fluoride, 1 mM dithiothreitol and 
0.1 mM EGTA. Cells were then swollen on ice for 15 min. After the addition of 25 µL 
of 10% Nonidet-40 (buffer B), cells were vigorously vortexed for 10 s. After 10 min 
incubation on ice, the broken cells were successively spun for 10 min at 3000 x g and 
for 5 min at 14,000 x g. The pellet was resuspended in 50 µL of buffer C consisting of 
20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM 
phenylmethylsulphonyl fluoride and 1 mM dithiothreitol. Solutions A, B, C and PBS 
were supplemented with the protease inhibitor cocktail Complete. After a 90-min of  
gentle shaking at 4°C, the nuclei were pelleted by a 5 min spin at 2000 x g. The
supernatant containing nuclear proteins was collected and the protein amount was 
determined by the Lowry assay.
TNF- release determination
Page 6 of 36
John Wiley & Sons, Inc.
GLIA
The amount of TNF- released into the culture medium was determined with an ELISA 
kit specific for mouse TNF- (Diaclone, Besançon, France). The ELISA assay was 
performed following the instructions supplied by the manufacturer.
Western blot
15-20 µg of protein of denatured (5 min, 100°C) nuclear extracts were subjected to 
SDS-PAGE on a 15% polyacrylamide gel and transferred to a PVDF membrane. The 
membranes were processed as follows: 1) 5 min in Tris-buffered saline (TBS, 20 mM 
Tris, 0.15M NaCl, pH=7.5); 2) 10 s in methanol; 3) air dry; 4) overnight incubation at 
4°C on primary antibody (rabbit anti- NF-B 1:500 or mouse anti p21 1:2000 or rabbit 
anti-p36 1:5000) diluted in immunoblot buffer (TBS containing 0.05% Tween-20 and 
5% nonfat dry milk); 5) 2x 15 s in TBS 0.05% Tween-20; 6) 1 hour in HRP-labelled 
anti mouse or anti-rabbit antibody diluted 1:5000 in immunoblot buffer; 7) extensive 
washes in TBS-0.05% Tween-20; 8) 5 min in ECL-Plus. Membranes were exposed to 
the camera of a VersaDoc system and chemiluminescence was quantified using 
Quantity One 5.4.1 software. For each antibody used, we verified the linearity between 
the level of chemiluminescence in de western blots and the amount of protein loaded. 
Linearity was observed in a range of 10 to 40 µg of protein.
Immunocytochemistry
For immunocytochemistry, cultured cells were fixed with 4 % paraformaldehyde for 20 
min at room temperature. When immunocytochemistry was revealed with 
diaminobenzidine, the protocol was: 7 min in 0.3% H2O2 in methanol, 2 x 15 min in 
PBS, overnight in primary rabbit anti NF-B antibody (1:500) or  mouse anti p21 
antibody (1:500), 2 x 15 min in PBS, 1 h in biotinylated anti-rabbit or biotinylated anti 
mouse antibody (1:200), 2 x 15 min in PBS, 1 h in ExtrAvidin-HRP (1:500), 5-10 min 
in diaminobenzidine (1 mg/ml)- 0.15% H2O2 in PBS. All steps were performed at room 
temperature except the primary antibody incubation (4°C). All antibodies were diluted 
in PBS containing 10% normal goat serum. 
The cellular localization of p21Cip1 expression after treatment with A peptides 
was determined by double immunocytochemistry, immunofluorescence labelling was 
carried out in cells where p21Cip1 immunoperoxidase labelling had been performed. A 
rabbit anti-glial fibrillary acidic protein (GFAP) polyclonal antibody (1:2000) was used 
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	to label astroglial cells and an anti-CD11b monoclonal antibody (1:500) was used to 
label microglial cells. Cells were incubated with the primary antibodies in 1% goat 
serum overnight at 4°C, and with goat anti-rabbit ALEXA 488 and goat anti-mouse 
ALEXA 546 secondary antibodies (1/500) in 1% goat serum for 1 h at room 
temperature. After extensive washing in PBS, cells were stored at 4°C. All samples 
were photographed on an Olympus fluorescence microscope equipped with a digital 
camera Color View 12 powered by a HBO 100 lamp.
Quantitative Real-Time PCR
Total RNA was isolated with Absolutely RNA Miniprep kit and reverse transcribed 
with random primers using Sensiscript-RT. The primers used to amplify mouse p21Cip1
mRNA were 5'-ATGTCCAATCCTGGTGATGT-3' (forward) and 5'-
TGCAGCAGGGCAGAGGAAGT-3' (reverse). The primers used to amplify mouse  the 
toll-like receptor 4, TLR4 mRNA were 5'-CCTCTGCCTTCACTACAGAGACTTT-3' 
(forward) and 5'-TGTGGAAGCCTTCCTGGATG-3' (reverse). To normalise of Ct 
values to an endogenous control the following mouse actin mRNA primers were used: 
5’-CAACGAGCGGTTCCGATG-3’(forward) and 5’-
GCCACAGGATTCCATACCCA-3’(reverse). Real time PCR was carried out with IQ 
SYBRGREEN SuperMix and iCycler IQ equipment. Primer efficiency was estimated 
from standard curves generated by dilution of a cDNA pool. Samples were run for 40 
cycles (30 sec 95ºC, 1 min 55ºC, 30 sec 72 ºC). Two samples per condition were 
analyzed in triplicate in each experiment and 3 independent experiments were 
performed. 
Preparation of fibrillar and oligomeric A peptides
 A peptide was prepared according to the protocol described by (Dahlgren et al. 2002). 
Briefly, A was dissolved in hexafluoroisopropanol, desiccated and dissolved in 
dimethyl sulfoxide to 5 mM. This solution was brought to 100 µM by dilution in 10 
mM HCl, aged for 24 hours at 37ºC (Fibrillar) or diluted in Ham-phenol free and aged 
for 24 hours at 4ºC (Oligomeric). After 24 h of aging, the two A forms were 
immediately applied to the cells at the required concentration.
Cell viability
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Cell viability was routinely estimated by fluorescent staining. Twenty-four hours after 
the different treatments cells were incubated with propidium iodide (4.6 µg/ml) for 5 
min and then examined under a fluorescence microscope (Olympus IX70). Propidium 
iodide-positive dead cells showed red nuclei. Images of 4 microscopic fields in each 
well were obtained with a digital camera (ColorView 12) using a 20X objective. Three 
wells per experimental condition were processed and three independent experiments 
were performed.
Total cell number was measured by Hematoxilyn nuclear  staining. Twenty-four hours 
after the different treatments, fixed cells were washed with PBS before incubation with 
Hematoxilin for 1 min. After three washes with tap water, cells were examined under a  
microscope (Olympus IX70). Images of 3 microscopic fields in each well were obtained 
with a digital camera (ColorView 12) using a 20X objective. Three wells per 
experimental condition were processed and three independent experiments were 
performed. Visual counting of nuclei was performed with the imaging analysis software 
“analy-SIS” (Soft Imaging System GmbH, Germany). 
Statistical analysis
The statistical analysis was performed using one-way ANOVA followed by Dunnett’s 
post-hoc test (TLR4 and p21Cip1 mRNA determination) or Student’s t-test (Western blot 
quantification and TNF- release determination). Differences were considered 
significant if p<0.05.  
Results
Cell viability and cell number
Propidium iodide staining showed that cell viability was  95% after 24 hours of any 
cell treatment in each type of glial culture. In addition, the number of cells in each glial 
cell culture was estimated after the different treatments. There were not significant 
differences between the number of control cells and the number of treated cells in any 
glial culture type after 24 hours of treatments (Table I).
TNF- expression is dependent on p21Cip1 in microglial cells 
Figure 1A shows the results obtained in microglia enriched cultures. The increase in 
TNF- released by microglia in the culture medium 24 h after LPS treatment was higher 
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(p< 0.05, Student’s t test) in p21 Cip1-/- than in wild-type cultures (13.2 pg/mL in wild-
type mice microglia and 26.3 pg/mL in p21Cip1-/- mice microglia). However, in 
astrocyte-enriched cultures, there were no significant differences between wild-type 
astrocytes and p21Cip1-/- astrocytes (Figure 1B). These results suggest that, microglial 
cells are responsible for the higher increase in TNF- release in glial cells from p21Cip1-/- 
mice. 
The increase in the NF-B expression is reduced in p21Cip-/- glial cells
We observed NF-B nuclear translocation both in wild-type and p21Cip1-/- mixed glial 
cultures 24 hours after LPS treatment (Figure 2). However, NF-B nuclear translocation 
was reduced in p21Cip1-/- cultures. Figure 2A shows a representative Western blot from 
nuclear extracts of mixed glial cultures. The quantification of Western blots shows that 
p65 increased 2.3±0.8 fold (1.22±0.22 in LPS treated cells versus 0.51±0.09 in control 
cells, n= 3, p<0.01 Student’s t test) after LPS treatment in wild-type cultures and 1.2 
fold (not significant, n.s.) in p21Cip1-/- cultures. Similar results were also given by 
immunocytochemistry (Figure 2B) after LPS treatment: the increase in NF-B nuclear 
translocation was lower in p21Cip1-/- glia than in wild-type glia.
In microglia-enriched cultures, an increase in NF-B nuclear translocation was observed 
in wild-type cultures after LPS treatment. This was revealed by both Western blot and 
immunocytochemistry (Figure 3). The increase in NF-B nuclear translocation was 
lower in p21Cip1-/- microglia. The increase was 1.89±0.14 (1.92± 0.12 in LPS treated 
cells versus 0.91±0.06 in control cells, n=3, p<0.001) times the control value in wild-
type microglia and 1.4 (n.s) times in p21Cip1-/- microglia after 24 h of LPS treatment. 
Figure 3B show p65 nuclear translocation in the different experimental conditions, as 
revealed by immunocytochemistry. The effect was similar to that shown by Western 
blot.
In astrocyte-enriched cultures, the increase in NF-B nuclear translocation after LPS 
was lower in p21Cip1-/- than in wild-type cultures (Figure 4). Quantification of Western 
blots after LPS treatment (Figure 4A) showed 1.71±0.36 fold increase in the control 
value in wild-type astrocytes (1.53±0.27 in LPS treated cells versus 0.90±0.06 in control 
cells, n=3, p<0.05), while there was no detectable increase in p21Cip1-/- astrocytes. The 
same effect was observed by immunocytochemistry (Figure 4B).
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The study of both cell types together (mixed cultures) or the study of each cell type 
individually (either astrocytes or microglia) showed that, either way, p21Cip1-/- glial cells 
had a reduced capacity to translocate NF-B into the nucleus.
TLR4 expression
The toll-like receptor 4 (TLR4) is the receptor for LPS-dependent signalling (Heine et 
al., 1999). For this reason, we studied whether the LPS treatment produced different 
expression of TLR4 in glial cells from wild-type and p21Cip1-/- mice. Figure 5 shows the 
results obtained by quantitative real time PCR. No differences in the basal expression of 
TLR4 were observed between wild-type and p21Cip1-/- glial cells. LPS treatment caused a 
similar decrease in TLR4 mRNA expression in wild-type and p21Cip1-/- glial cells. We 
did not observe any differences in TLR4 protein expression by immunocytochemistry 
(data not shown). These results suggest that TLR4 expression is not modified in p21Cip1-
/- glial cells. 
p21Cip1 expression increases during glial activation 
We were interested to study whether LPS induced changes in p21Cip1 expression in glial 
cells. In mixed glial cultures LPS significantly increased p21Cip1mRNA levels 2h after 
treatment (1.8-fold increase, P<0.01). P21Cip1 returned to control levels 4 h after LPS 
(Figure 6A). The observed increase was accompanied with an increase in p21Cip1 protein 
expression. A time-course experiment revealed that nuclear p21Cip1 increased from 4 h 
post-treatment and the increase was maximal after 16-24 h (data not shown). 
Cycloheximide pre-treatment (50 µM, 30 min before LPS) completely prevented the 
protein increase (Figure 6B). We also studied the effect of LPS on p21Cip1 protein 
expression 24 h after treatment in the three different types of glial cultures. Figure 7A 
shows the results obtained in mixed glial cultures. Western blots show that LPS 
treatment caused an increase of 2.51±0.81 times the control value (2.03±0.49 in LPS 
treated cells versus 0.82±0.23 in control cells, n=3, p<0.05). In Figure 7D, a and d 
panels show the results obtained by immunocytochemistry: a strong increase in p21Cip1 
immunolabeling after LPS treatment was observed.
In microglia-enriched cultures, the increase of p21Cip1 produced by LPS treatment was 
also very clear. LPS treatment resulted in an increase that was 2.62±0.33 times the 
control value (1.59±0.02 in LPS treated cells versus 0.61±0.08 in control cells, n=3, 
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p<0.001) (Figure 7B). The images obtained by immunocytochemistry were consistent 
(figure 7D, panels b and e) with the results obtained by Western blot.
In astrocyte-enriched cultures, there was an increase of p21Cip1 protein after LPS 
treatment that was 1.54±0.36 times the control value (2.76±0.51 in LPS treated cells 
versus 1.80±0.08 in control cells, n=3, p<0.05) (Figure 7C). The images obtained by 
immunocytochemistry (Figure 7D, panels c and f) are consistent with those obtained by 
Western blot.
Treatment with A increases p21Cip1 expression in glial cultures
In addition to the LPS treatment, we also examined the effect of A treatment on NF-B 
nuclear translocation, TNF- release and p21Cip1 expression in glial cells. Both 
oligomeric and fibrillar A were used.
Figure 8A shows the results obtained by Western blot on NF-B translocation after 
treatment with LPS or the two types of A. In this group of experiments LPS treatment 
of wild-type glial cell cultures (used as a positive control of glial activation) produced a 
strong increase of 5.61±1.02 times the control value in nuclear NF-B content 
(2.83±0.38 in LPS treated cells versus 0.40±0.08 in control cells, n=4 p<0.001). 
Fibrillar A produced an increase of 3.78±1.69 fold (1.55±0.46 in A treated cells 
versus 0.40±0.08 in control cells, n=4, p<0.01). Oligomeric A did not produce any 
effect. In glial cultures from p21Cip1-/- mice, LPS produced a lower increase than in wild-
type: 2.3±0.57 times the control value (2.22±0.51 LPS treated cells versus 0.96±0.21 in 
control cells, n=4, p<0.01). After treatment with A forms, no NF-B nuclear 
translocation was observed.
Figure 8B shows a mixed culture by phase contrast microscopy 24 h after the different 
treatments. Panels a, and b correspond to control cells from wild-type and p21Cip1-/- 
mice, respectively. These images are very similar to those from cultures 24 h after 
treatment with oligomeric A (Figure 8B, c and d). However, treatment with fibrillar 
A (Figure 8B, e and f) induced a change in the morphology of the cultures. The 
smaller refringent cells, corresponding to microglial cells, were not observed. This 
effect was detected both in wild-type and in p21Cip1-/- cultures. After LPS treatment, the 
two cultures (figure 8B, g and h) had the same appearance as the control cells or the 
cells treated with oligomeric A.
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We also analysed the effect of LPS and A peptide treatments on TNF- release into the 
culture medium. There were no significant differences between the control and 
treatment values either type of mixed glial cultures (wild-type and p21Cip1-/- mice). LPS 
induced a TNF- release in wild-type which was significantly higher in p21Cip1-/- glial 
cultures. A did not induce TNF- release in wild-type or p21Cip1-/- (results not shown).
Figure 9 shows the p21Cip1 protein expression after treatment with the two types of A
or LPS. Figure 9A shows a Western blot obtained after the different treatments. The 
quantification of Western blots showed that fibrillar A treatment resulted in 4.06±0.83
times more p21Cip1-/- protein expression than in control (5.78±2.82 in fibrillar A treated 
cells versus 1.4±0.52 in control cells, n=4, p<0.05). There were no differences between 
treated cultures and the control after A oligomeric treatment. LPS treatment resulted in 
an increase of 2.05±0.08 times more than the control value (2.86±0.99 in LPS treated 
cells versus 1.4±0.52 in control cells, n=4, p<0.05). The Western blots obtained from 
p21Cip1-/- mixed glial cultures did not present the p21Cip1 band. This negative control was 
used to verify antibody specificity. Figure 9B shows the results of 
immunocytochemistry. A strong increase in p21Cip1 expression was observed after 
fibrillar A (Figure 9B, e) or LPS treatment (Figure 9B, g). Oligomeric A treatment 
(Figure 9B, c) produced a weaker increase. Panels b, d, f and h in Figure 9 B correspond 
to treatments carried out with cultures from p21Cip1-/- mice. No immunoreactivity was 
observed, indicating the specificity of the p21Cip1 antibody.
Figure 10 shows a double immunostaining, carried out to find out wether p21Cip1
increases after fibrillar A treatment in the two cell types contained in the mixed culture 
(microglia and astrocytes). The results show that there was a p21Cip1 increase in both 
microglia (Figure 10, a,b) and astrocytes (Figure 10, c and d).
Discussion
In a preliminary study (Tusell et al., 2005), we examined possible differences in the 
process of glial activation between mixed glial cultures (microglia and astrocytes) from 
wild-type and p21Cip1-/- mice.  We compared the effect of serum mitogenic stimulation 
on proliferation rate and on the total number of glial cells. No differences between wild-
type and p21Cip1-/- were observed. We also compared the effect of LPS on NO and TNF-
 release and nuclear NF-B translocation as indicators of glial activation. We observed 
an attenuation of NO release and NF-B activation in p21Cip1-/- glial cells when 
Page 13 of 36
John Wiley & Sons, Inc.
GLIA

compared with glial cells from wild-type mice. In contrast TNF- was enhanced in 
p21Cip1-/-. These results suggest that the role of p21Cip1 in the glial inflammatory 
response does not depend on its function as an inhibitor of cell proliferation. In the 
present study, we further examined the role of p21Cip1 in glial activation to determine 
whether it differentially contributes to astroglial and microglial activation. Thus, we 
studied the role of p21Cip1 in glial activation using mixed, microglial-enriched and 
astroglial-enriched glial cultures (with above 95% purity for each cell type). In the 
aforementioned study, we evaluated the effect of LPS, an agent widely used to induce 
glial activation. In the present study, we extended this work by using two forms of the 
peptide A. Finally, we also examined the way in which the different treatments 
affected p21Cip1 protein expression. As glial activation indicators, we measured TNF-
release into the culture medium and NF-B nuclear translocation. The results confirm 
that mixed glial cells from p21Cip1-/- mice had a higher increase of TNF- release in 
response to LPS. However we demonstrated that this effect was basically caused by 
microglial cells (Figure 1A, B) rather than astrocytes.
Mixed, astroglial and microglial cultures from wild-type mice increased NF-B 
translocation after LPS treatment. However, glial cultures from p21Cip1-/- mice had a 
reduced capacity to activate NF-B. In contrast, TNF- release was increased in LPS-
treated p21Cip1-/- glial cells compared with glial cells from wild-type mice, specifically 
in microglia. Our results show that these changes are not due to differences in glial cell 
viability between cells from wild-type and p21Cip1-/- mice. The changes are neither due 
to differences in TLR4 expression between glial cells from wild-type and p21Cip1-/- mice. 
This receptor is required for the transduction of LPS signals in monocytes and 
macrophages (Qureshi et al., 1999). Microglia is the most important cell type in the 
resting CNS that expresses TLR4 (Lenhardt et al., 2003). This receptor is responsible, in 
part, for microglial activation in response to LPS (Kitamura et al., 2001; Qin et al., 
2005). Systemic LPS administration to rats and mice induces a robust increase in TLR2 
expression in the CNS, whereas TLR4 is reduced (Laflamme et al., 2001, 2003). Our 
results show that no differences are observed in basal TLR4 expression between glial 
cells from wild-type or p21Cip1 mice. In addition, we detected a similar decrease in 
TLR4 expression after LPS treatment in mixed glial cultures from wild-type and 
p21Cip1-/- mice.
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As NF-B is one of the transcription factors involved in the inflammatory response 
given by activated glial cells, the reduced capacity to activate NF-B we observed in 
p21Cip1-/- glial cultures suggest that p21Cip1 is actively involved in this inflammatory 
response both in astrocytes and microglia, acting as a positive regulator of NF-B 
activation. Activation of NF-B followed by increased TNF- production has been 
repeatedly described in reactive glial cells. In addition, as LPS and other cytokines, 
TNF- is able to induce NF-B translocation and glial activation. However, although 
we observed an increase in both NF-B activation and TNF- production in wild type 
cultures in response to LPS, the absence of p21Cip1 resulted in a reduced activation of 
NF-B but in an increased production of TNF- in p21Cip1-/- cultures. These results 
suggest that p21Cip1 acts as an inhibitor of TNF- in LPS-induced glial activation. The 
differences observed between microglial and astroglial cells from p21Cip1-/- cultures as 
regards LPS-induced TNF- production may be due to a differential regulation of TNF-
 production in each glial cell type. In relation to that, TNF- production in response to 
different stimuli is usually higher in microglial than in astroglial cells.
We have described for the first time a possible relationship between p21Cip1 expression,
TNF- release and NF-B translocation in cells of the CNS, and it is difficult to explain 
the opposite effects observed in NF-B and TNF- production in glial activation in the 
absence of p21Cip1. There is a previous work showing a relationship between TNF-, 
NF-B activation and p21Cip1 expression in human epithelial cells: TNF- induced 
growth arrest in these cells is mediated by NF-B-dependent increase in p21Cip1
expression (Basile et al., 2003). In our case, the effects observed in p21Cip1-/- cultures do 
not appear to be related to alterations in cell proliferation (Tusell et al., 2005), 
suggesting additional roles for p21Cip1. One possibility is that, in reactive glial cells, 
p21Cip1 may be involved both in the inflammatory response and in the resolution of the 
inflammation by a still unknown mechanism, on the one hand facilitating NF-B action 
and on the other hand limiting glial activation, specially in microglial cells, through the 
inhibition of TNF- which otherwise could result in overactivation of NF-B. In 
addition, as TNF- produced by reactive glial cells has been shown to be neurotoxic to 
neurons (Feuerstein et al., 1998; Takeuchi et al., 2006; Kaushal and Schlichter, 2008), 
the presence of p21Cip1 in glial cells may be important to prevent neurotoxicity induced 
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by reactive glia. Further studies are needed to establish the mechanism of action of  
p21Cip1 in glial activation.
LPS-treated glial cells show an increase in p21Cip1 at mRNA and protein levels due to de
novo synthesis. These results further suggest that p21Cip1is involved in glial activation. 
They are in agreement with the results obtained by Ring et al. (2003) in an in vivo study 
that used LPS as a model for acute inflammation. These authors reported that p21Cip1 is 
induced in the mouse CNS as part of the acute response to inflammation, suggesting 
that this induction is a cytokine signalling event, involving TLR4.
Finally, we observed that neither the oligomeric nor the fibrillar A form modified 
TNF- release in mixed glial cultures of wild-type or p21Cip1-/- mice. Although an 
increase in NF-B translocation was observed in wild-type cultures treated with fibrillar
A, no effect was observed in p21Cip1-/- cultures. However, we did observe a change in 
the appearance of the glial cultures treated with fibrillar A both in wild-type and 
p21Cip1-/- glia. Similarly, we observed an increase in p21Cip1 expression in glial cells 
treated with the fibrillar form, but not in those treated with the oligomeric form. In a 
previous study, we showed that the effect of A on microglial activation depended on 
the aggregation state of the peptides (Casal et al., 2002). It is unclear how the difference 
in the aggregation of peptides accounts for the difference in bioactivity. However, 
particular conformations of peptides could determine the receptor activation potential, 
due to secondary and tertiary peptide conformations. In some cases, these 
conformations might be incapable of efficient binding and activate glial receptors that 
induce immune activation and inflammatory cascades. Thus, as we observed after LPS 
treatment, wild type glial cells treated with fibrillar A show NF-B activation and 
induction of p21Cip1 expression, and NF-B activation is inhibited in the absence of 
p21Cip1. Nevertheless, the magnitude of the effects observed is lower after fibrillar A
treatment, what may account for the absence of effect in TNF- release observed.
In summary, the present results implicate p21Cip1 protein in glial activation. The 
mechanisms involved in the expression of this protein and TNF- activation or NF-B 
activation need to be studied further. There are probably other molecules involved. 
Preliminary studies that are underway in our laboratory suggest that some transcription 
factors from the C/EBPs family require p21Cip1 to be activated during glial activation. 
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Moreover, the increases in p21Cip1 after treatment with fibrillar A peptide suggest that 
p21Cip1 may be involved in the chronic glial response in Alzheimer’s disease.
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Table I. Cell number 24 hours after treatment in mixed, microglial and astrocyte 
cultures. WT= wild-type cultures. KO= p21Cip1-/- cultures. C= control cells (culture 
medium). LPS= cells treated with LPS, OLG= cells treated with oligomeric A form. 
FIB= cells treated with fibrillar A form. NT= non tested. Data are means ± SD from 
three independent experiments. 
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Figure Legends
Figure 1. TNF- release in microglia-enriched cultures (A) and in astrocyte-enriched 
cultures (B) from wild-type (WT) and p21Cip1-/- (KO) mice 24 h after LPS treatment. 
Bars represents the means ± SD of five independent experiments. Data were expressed 
as a quotient between LPS treated cells versus their control value. *p<0.05, Student’s t
test.
Figure 2. Nuclear translocation of NF-B in mixed glial cultures from WT and KO 
mice using an anti-p65 subunit antibody. (A) Western blot from nuclear extracts of 
mixed glial cultures after 24 h of LPS treatment. p36 was used as a loading control. This 
western blot is representative of three independent experiments. (B) 
Immunocytochemistry of the mixed glial cultures using the anti-p65 subunit antibody; a 
and b control glial cells from wild-type and p21Cip1-/- mice, respectively; c and d glial 
cells after 24 h of LPS treatment. Images are representative of at least three independent 
experiments. Bar= 50µm. Arrowheads point out cell nuclei.
Figure 3. Nuclear translocation of NF-B in microglial-enriched cultures from WT and 
KO mice using the anti-p65 subunit antibody. (A) Western blot from nuclear extracts of 
microglial cells after 24 h of all treatments. p36 was used as a loading control. This 
Western blot is representative of three independent experiments. (B) 
Immunocytochemistry of the microglial cultures using the anti-p65 subunit antibody; a 
and b control microglial cells from wild-type and p21Cip1-/- mice, respectively; c and d 
microglial cells after 24h of LPS treatment. Images are representative of at least three 
independent experiments. Bar= 50µm. Arrowheads point out cell nuclei.
Figure 4. Nuclear translocation of NF-B in astroglial-enriched cultures from WT and 
KO mice using the anti-p65 subunit antibody. (A) Western blot from nuclear extracts of 
astrocytic cells after 24 h of all treatments. p36 was used as a loading control. This 
western blot is representative of three independent experiments. (B) 
Immunocytochemistry of the astrocyte cultures using the anti-p65 subunit antibody; a 
and b control astroglial cells from wild-type and p21Cip1-/- mice, respectively; c and d 
astroglial cells after 24h of LPS treatment. Images are representative of at least three 
independent experiments. Bar= 50µm. Arrowheads point out cell nuclei.
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Figure 5. TLR4 mRNA expression in mixed glial cells. After 6h of LPS treatment no 
differences between WT and P21Cip1 KO were observed. Bars represent the means ± SD 
of three independent experiments, normalized versus control values. The statistical 
analysis was performed using one-way ANOVA followed by Dunnett’s post-hoc test. 
*p<0.05 versus their control value.
Figure 6. p21Cip1 expression in LPS treated mixed glial cultures. (A) Real-time PCR 
analysis of p21Cip1 mRNA expression induced by LPS. Cycle thresholds normalized to 
actin were used to calculate p21Cip1 mRNA levels. Bars represent the means ± SD from 
four independent experiments. The statistical analysis was performed using one-way 
ANOVA followed by Dunnett’s post-hoc test.*p<0.01 versus control. (B) Expression 
of p21Cip1 protein. Cells were treated with LPS ± cycloheximide (CHX, 50 µM) for 16 
h. This is a representative Western blot of three independent experiments probed for 
p21Cip1 and for p36 as loading control.
Figure 7 Expression of p21Cip1 in glial cells after LPS  treatment. A, B and C show the 
Western blots from mixed glial cultures (A), microglial-enriched cultures (B), and 
astroglial-enriched cultures (C) from wild-type (WT) and p21Cip1-/- mice (KO) using an 
anti-p21Cip1 specific antibody. Results were obtained after 24h of LPS treatment. Actin 
was used as a marker of protein loading. The Western blots are representative of three 
independent experiments. (D) shows the results obtained by immunocytochemistry 
using the anti-p21Cip1 antibody; a, b, and c control cells from mixed glial cultures, 
microglial-enriched cultures and astroglial-enriched cultures respectively; d, e and f 
show the images from each cell culture type obtained after 24h of LPS treatment. 
Images are representative of at least three independent experiments. Bar=50µm. 
Arrowheads point out cell nuclei.
Figure 8. Effect of A peptide forms in glial cells. (A) shows the western blot of 
nuclear extracts from mixed glial cultures from WT and KO mice using the p-65 
subunit antibody after 24h of treatment with the oligomeric A form (OLG) and with  
fibrillar A (FIB). LPS was used as a positive control of glial activation after 24h of the 
treatment. p36 was used as a loading control. This Western blot is representative of 
three different experiments. (B) shows the appearance by phase contrast microscopy of 
the mixed glial cells 24h after the diverse treatments; a and b show the control mixed 
glial cells from wild-type and p21Cip1 mice respectively; c and d show the glial cells 
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after treatment with the OLG; e and f show the changes in cell appearance after 
treatment with FIB; g and h show the aspect of the glial cells after LPS treatment. 
Images are representative of at least three independent experiments. Bar= 50µm.
Arrowheads point out cell nuclei.
Figure 9. Effect of A peptide forms on p21Cip1 expression in mixed glial cultures. (A) 
shows the western blot from nuclear cell extracts using the ant-p21Cip1 antibody. Mixed 
glial cultures from KO were used as a negative control to verify the specificity of the 
p21Cip1 antibody. This Western blot is representative of three independent experiments. 
p36 was used as a loading control. (B) shows the immunocytochemistry after 24h of all 
treatments. p21Cip1-/- mixed glial cells (b, d, f, h) were used to verify the antibody 
specificity. a and b show control cells from WT and KO respectively; c and d show glial 
cells after treatment with OLG; e and f are glial cells after FIB treatment; g and h are 
glial cells after LPS treatment. Images are representative of at least three independent 
experiments. Bar= 50µm. Arrowheads point out small refringent cells.
Figure 10. Expression of p21Cip1 in mixed glial cultures after 24h of FIB treatment. The 
p21Cip1 expressing cells in mixed glial cultures were detected by double 
immunocytochemistry. Images show p21Cip1 immunolabelling (left column, a and c) and 
CD11b or GFAP immunofluorescence respectively (right column, b and d). After 24h 
of treatment with FIB, nuclear expression of p21Cip1 was observed in CD11b positive 
cells (microglia, arrowheads in a, b) and in GFAP positive cells (astrocytes, arrowheads 
in c, d); a, and b are in the same microscopic field; c and d are in the same microscopic 
field. Bar=50µm.
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